Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Post by jewel9mon Jun 21, 2016 8:01pm
132 Views
Post# 24985564

Potential partner picks...

Potential partner picks...1)Allergan complete buyout
2)Allergan 1067 buyout
3)Allergan 1067 upfront license

If you look since the excitement back in late January, The deal between Allergan and Teva was supposed to close in March. Management was very excited about making a deal with Allergan, once Allergan closed its deal with Teva. Unfortunately the FDA got very nervous on antitrust and is forcing Teva to sell $2 billion in assets before they will allow the deal to go thru. TEVA and Allergan then changed their closing date until June. So Sirona management has to wait until Teva and Allergan comply with the FDA. So far they are about half way there and still expect to complete the deal in June. 
Dont forget in all this Pfizer was going to buy Allergan. That got shut down and I think Allergan said to Sirona, "Not until June when the Teva deal closes."
So here we sit.
If the Teva deal closes in June, then there is a slight possiblity that Sirona and Allergan will close in June. If not then I would fully expect July.
Sirona may have other offers, but until Allergan walks away they are the smart choice.
For me there are no other logical reasons why management seemed so confident in January and did not close a deal. Is was also noted in the presentation that one potential partner was in merger talks. Who is that?? Allergan.
Also, check out Sedi, management is heavliy invested in this. They have the most to gain and loose if a deal cannot be worked out.
I think they are playing this well. Going to industry shows and events and keeping active. 
From my experience investors, and rightly so, get the most nervous when deals are very close, patience and risk tolerance either keep you in or send you out.
I have not found anything in my DD that would make me sell now. Share price fluctuations are hard on the nerves but the volume is low and certain house are still accumulating.
IMHO
 
 



Bullboard Posts